Clinical Trial Update: A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of APG-2575 by Ascentage Pharma for chronic lymphocytic leukemia and non-Hodgkin lymphoma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• APG-2575

Snippet

Sponsor: Ascentage Pharma Group Inc. | Conditions: Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING